3-Alkyl-4-sulfamoyl-aniline therapeutic compositions
    6.
    发明授权
    3-Alkyl-4-sulfamoyl-aniline therapeutic compositions 失效
    3-烷基-4-氨磺酰基 - 苯胺治疗组合物

    公开(公告)号:US3991188A

    公开(公告)日:1976-11-09

    申请号:US593089

    申请日:1975-07-03

    IPC分类号: A61K31/63 A61K31/625

    CPC分类号: A61K31/63 Y10S514/869

    摘要: New 3-alkyl-4-sulfamoyl-aniline compounds of the formula ##SPC1##WhereinR.sub.1 is phenyl, furyl or thienyl;R.sub.2 is carboxyl or tetrazolyl-(5)R.sub.4 is a straight-chain or branched alkyl radical of from 2 to 5 carbon atoms; andn is 1 or 2;And the pharmacologically compatible salts thereof; are outstandingly effective saluretic compounds, particularly when administered enterally.

    摘要翻译: 式WHEREIN R1的新的3-烷基-4-氨磺酰基 - 苯胺化合物是苯基,呋喃基或噻吩基; R2是羧基或四唑基 - (5)R4是2至5个碳原子的直链或支链烷基; 和N IS 1 OR 2; 及其药理学兼容性; 具有非常有效的挥发性化合物,特别是在进行管理时尤其如此。

    Pyrrolobenzimidazoles, pharmaceutical compositions containing them and
method of using them to treat certain heart and circulatory diseases
    7.
    发明授权
    Pyrrolobenzimidazoles, pharmaceutical compositions containing them and method of using them to treat certain heart and circulatory diseases 失效
    吡咯并苯并咪唑,含有它们的药物组合物和使用它们治疗某些心脏和循环系统疾病的方法

    公开(公告)号:US4695567A

    公开(公告)日:1987-09-22

    申请号:US820259

    申请日:1986-01-17

    摘要: The present invention provided pyrrolobenzimidazoles or tautomer thereof, of the general formula: ##STR1## wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.3 -C.sub.7 cycloalkyl;R.sub.2 is hydrogen, cyano, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, or a carbonyl group substituted by hydroxyl, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkyoxy, amino, C.sub.1 -C.sub.6 alkylamino, C.sub.2 -C.sub.12 dialkylamino or hydrazino, orR.sub.2 and R.sub.1 together with the carbon to which they are attached form a C.sub.3 -C.sub.8 spirocycloalkyl ring, or R.sub.1 and R.sub.2 together form C.sub.3 -C.sub.7 alkylidene or C.sub.3 -C.sub.7 cycloalkylkidene,X is a valency bond, C.sub.1 -C.sub.4 alkylene or vinylene andT is oxygen or sulphur;and Het is furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl wherein the heterocyclic five- and six-membered rings are unsubstituted or substituted by one or more C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, hydroxyl, oxo, nitro, amino, halo, carboxyl, C.sub.2 -C.sub.7 alkoxycarbonyl, aminocarbonyl or cyano groups; or a physiologically acceptable salt thereof with an inorganic or organic acid. These compounds are useful for treating heart or circulatory diseases, especially those which respond to a change of blood pressure, an increase in cardiac output and/or a change in micro-circulation.

    摘要翻译: 本发明提供了以下通式的吡咯并苯并咪唑或其互变异构体:其中R 1是氢,C 1 -C 6烷基,C 2 -C 6烯基或C 3 -C 7环烷基; R2是氢,氰基,C1-C6烷基,C2-C6烯基或被羟基,C1-C6烷基,C1-C6烷氧基,氨基,C1-C6烷基氨基,C2-C12二烷基氨基或肼基取代的羰基或R2 并且R 1与它们所连接的碳一起形成C 3 -C 8螺环烷基环,或者R 1和R 2一起形成C 3 -C 7亚烷基或C 3 -C 7环烷基,X是价键,C 1 -C 4亚烷基或亚乙烯基,T是 氧或硫; 并且Het是呋喃基,噻吩基,吡咯基,吡唑基,咪唑基,恶唑基,噻唑基,三唑基,恶二唑基,噻二唑基,吡嗪基,嘧啶基或哒嗪基,其中杂环五元和六元环是未取代的或被一个或多个C 1 -C 6烷基 C 1 -C 6烷氧基,C 1 -C 6烷硫基,羟基,氧代,硝基,氨基,卤素,羧基,C 2 -C 7烷氧基羰基,氨基羰基或氰基; 或其生理上可接受的盐与无机或有机酸反应。 这些化合物可用于治疗心脏或循环系统疾病,特别是那些响应血压变化,心输出量增加和/或微循环变化的化合物。